Investor Presentation • Jun 14, 2021
Investor Presentation
Open in ViewerOpens in native device viewer


• 70-80% of Health budget
From 2020 situation burdened with Covid-19
SUSTAINABLE HEALTH SYSTEMS
We develop software, technologies and services to help innovating the models of care, assistance and prevention of the health care systems, optimizing processes and containing costs .
A partnership to make health systems sustainable and help improve people's health and well -being .

History of Growth
30 years of experience, management team with a track record of internal growth and M&As

International footprint
solutions used by 2,400 customers in more than 60 countries
Leadership
1st player in Italy: services granting access to care
2nd player in Italy: software solutions for healthcare and social systems

Uniqueness
integrated software, technology and service solutions to optimise the clinical, care, administrative and social processes.

Quality of life
our work helps improve the quality of life


Net Profit M€ Staff




Strategic Business Areas
Pay 3.3% Automation 4.4% ICT 5.5% Software 37.9%
SERVICES 48.9% Care
Notice: % revenue by SBA out of total revenue in FY 2020

Software
main SBAs
86.8% of total revenue
other SBAs
13.2 % of totalrevenue
ICT
Pay
Care
Real experiences concretely implementing the Group's vision
Telemedicine Software, wearables, technological and medical operational centre, services to monitor more than 55 thousand covid- or chronic-ill patients
Artificial Intelligence, consultancy, methodological innovation for the risk stratification and to prioritize the vaccine jabs based on demographic and clinical factors
Software solutions and devices for the queue management, ICT services and Contact Center services to improve the access to Covid diagnostic tests, reducing the waiting time from hours to minutes
The central point is the TAKING CARE of patients. Integrate the value of Persons with the value of Technologies.
• Contract awarded Region Lazio Multichannel mgmt svc Servizio ReCUP (AtC) € 64.8 M | 2+2 years | Gpi 70%
• Assets Haemonetics, USA (SW Blood Bank) \$ 11.3 M Rev. |35% EBITDA | 100 clients in the USA
• Medinfo Group (SW Blood Bank) € 3.9 M Rev. | 36% EBITDA| 60 clients NHS UK, Army (France, Belgium)
REVENUE: € 271.0 M +12.5% Organic growth +6.6%, inorganic growth +5.9%
EXPORT: € 23.9 M +20.0%
Blood Management Systems (Software)
EBITDA: € 40.2 M +24.6% Main contribution by SBA Software
€ 20.6 M amortisation (+ € 4,5 M vs 2019 mainly for M&A and R&D)
Tax management positive variation (realignment of non-fiscal recognised values on certain assets | patent box)
| M€ | 2020 | 2019 |
|---|---|---|
| Revenue & other income | 271.0 | 240.9 |
| Adjusted Revenue(1) | 250.9 | 223.3 |
| EBITDA | 40.2 | 32.2 |
| EBITDA % of adj. revenue |
16.0% | 14.4% |
| EBIT | 18.9 | 15.1 |
| Net profit | 12.3 | 9.8 |
€ 109.0 M (€ 91.3 M in 2019):
€ 117.6 M (€ 82.8 M in 2019)
| M€ | 2020 | 2019 |
|---|---|---|
| Net working capital |
109.0 | 91.3 |
| Non-current assets | 159.7 | 119.4 |
| Other operating assets/(liabilities) | (67.9) | (55.8) |
| NET INVESTED CAPITAL | 200.9 | 154.9 |
| Shareholders' equity | 83.3 | 72.1 |
| Net financial position |
117.6 | 82.8 |
| TOTAL SOURCES | 200.9 | 154.9 |
A3.1 CERVED Rating confirmed A- S&P |A3 Moody's | A-1 Fitch


* H-pub: public healthcare clients; H-Pri: private healthcare clients, NH-Pub: public non-healthcare clients; NH-Pri: private non-healthcare clients

*From fiscal year 2020, the business of the subsidiary Xidera, that was included in the SBA Software, is included in the SBA Care. Fiscal year 2019 figures were restated to reflect this change.

• 30%
• 42%
• 1-3 years
• € 20 M / year
• 2° player ITA
** Win ratio intended as % no. tenders won out of total bids.


*From fiscal year 2020, the business of the subsidiary Xidera, that was included in the SBA Software, is included in the SBA Care. Fiscal year 2019 figures were restated to reflect this change.

• 81%
• 4-6 years
• 1° player ITA
** Win ratio intended as % no. tenders won out of total bids.

Automated warehouse sales, maintenance and service fees
Desktop management services fees other system services
ePayment services POS rental and related software
Competitive environment and strategic guidelines
| Software | |||||
|---|---|---|---|---|---|
| Company | Brief description | Focus on HC |
Ranking | ||
| ICT solutions and related services for public and private healthcare providers. |
| 1st | |||
| ICT solutions, administrative and social-healthcare services for public and private healthcare providers. |
| 2nd | |||
| ICT solutions for the segments: finance, industry, telco&utilities and PA. |
Through dedicated healthcare division |
3rd | |||
| Software for hospital processes, orders and risk management Group reply part. |
| 4th | |||
| Digital transformation & ICT services for industries, energy, aerospace, healthcare, PA, etc. |
Through dedicated healthcare division |
5th |
Market Analysis
| Company | Brief description | Ranking |
|---|---|---|
| ICT solutions, administrative and social-healthcare services for public and private healthcare providers. |
1st | |
| Maintenance services for medical devices, operative in 17 different countries. |
N/A | |
| BPO services (e.g. cleaning, security, logistics and healthcare services). |
N/A | |
| Local supplier of services for healthcare and the educational segment, operates in the Region of Veneto. |
N/A | |
| Local supplier of services for healthcare , operates in the Region of Lazio. |
N/A |

\$ 68.8 B
value of the Global market for health care software + IT services in 2020 +8% 2021/2020
CAGR 20 – 25: 10.8% (Gartner Q1 2021) CAGR 20 – 24: 9.7% (Gartner Q4 2020) CAGR 19 – 23: 7.5% (Gartner pre Covid Q4 2019)


value of the Italian market for health care software + IT services in 2020
CAGR 20 – 25: 5.7% (Gartner Q1 2021) CAGR 20 – 24: 3.9% (Gartner Q4 2020) CAGR 19 – 23: 6.6% (Gartner pre Covid Q4 2019)
National Recovery and Resilience Plan
€ 4B for digitizing health care of which €1B for Telemedicine
Software for the Blood Management System, a strategic area for the Health Systems of all Countries

50 offices
INTERNATIONAL OFFICES IN Austria, France, Germany, Malta, Poland, Russia, Spain, USA
WORLDWIDE SOLUTIONS > 60 Countries

New targets estimated by equal scope of consolidation as of 31/12/2020

M&A Guidelines

M&A Guidelines Become a Major European Player

• Product Portfolio Evolution software|services| territories




ISIN: IT0005221517 Ticker: GPI:IM 15,909,539 Ordinary Shares Price: € 14.15 (11 June 2021) Capitalisation: € 225 M
Leadership and Uniqueness
Banca Akros (08/06/2021): € 15.20 Midcap | Tp Icap (07/05/2021): € 15.00 Intermonte SIM (20/04/2021): € 13.70
ISIN: IT0005221475 Ticker: WGPI Conversion ratio: 1:1 Strike price: € 9.50 p.s. Redemption trigger price: € 13,30 monthly average price


Via Ragazzi del '99, 13 - 38123 Trento T +39 0461 381515 [email protected]
Fabrizio Redavid C. +39 335 1035499 [email protected]
C. +39 340 8223333 [email protected]

The material in this presentation was prepared by GPI S.p.A. ("GPI" or the "Company") without any form of independent verification; it is general, basic information about the current business of GPI as at the date of this presentation. This information is supplied in summary form and is not complete. This presentation is provided for information only and is not an offer or solicitation of an offer of purchase or sale of securities, nor shall there be any sale or purchase of securities in any jurisdiction in which such an offer, solicitation or sale should be illegal before the registration or qualification in accordance with the laws on securities of that jurisdiction. It is intended exclusively by way of a presentation to investors and is provided for information only. This presentation does not contain all information that may be relevant to an investor.
The information contained in this presentation, including the forecast financial information, must not be considered as advice or recommendations to investors or potential investors in connection with the holding, purchase or sale of securities or other products or financial instruments and does not take into account any specific investment targets nor the financial position. Before acting, it is important to consider the adequacy of information in relation to such subjects and, in particular, independent financial advice should be taken. All securities and product transactions or financial instruments entail risks, which include, amongst others, the risk of adverse or unforeseen market, financial or political developments and, in international transactions, the foreign exchange risk. The information contained in this presentation is confidential and is supplied to the user for information only and cannot be reproduced, re-sent or further distributed to anyone else, nor published, entirely or partly, for any purpose. This presentation is only distributed to and intended for: (A) persons in the European Economic Area Member States (excluding the United Kingdom), who are classed as "qualified investors" under Article 2, paragraph 1, letter e) of Directive 2003/71/EC (as amended and complete with any implementing measures applicable in each Member State); (B) in the United Kingdom, professional investment qualified investors coming under Article 19 (5) of the 2005 Order (financial promotion), the Order of Financial Services and markets and/or companies with high shareholders' equity and other persons to whom it can be lawfully disclosed, pursuant to Article 49,
paragraph 2, letters a) to d) of the Order; and (C) other persons to whom this presentation can be legally distributed and disclosed in accordance with applicable laws (all those pursuant to points (A) to (C) above, indicated as "relevant persons").
The information contained in this presentation may include forecasts. Although the Company believes it has a reasonable basis on which to make the forecasts given in this presentation, GPI warns that forecasts are no guarantee of future performance and that the effective operating results, financial conditions and conditions of liquidity and development of the segment in which GPI operates may differ considerably from those effectively achieved or suggested by the declarations given in this presentation or made by the GPI management team. Past performance is also not a reliable indication of future performance.
GPI makes no promise to update or publicly review the forecasts, even if new information is revealed or for any other reason. The information and opinions given in this presentation or in the declarations made by the GPI management team are given as at the date of this presentation or any other date, if indicated, and are subject to change without notice. Do not rely on the information given in this presentation for any purpose. No express or implicit declaration or guarantee is given by GPI, its subsidiaries or the respective consultants, functionaries, employees and agents, as regards the accuracy of information or opinions or for any loss as may derive directly or indirectly from any use of this presentation or its contents. This presentation is not intended for distribution or use by any person or entity that is a citizen or resident of a place, country or other jurisdiction in which such distribution, publication, availability or use may be in conflict with laws or regulations or which would require any registration or licence within such jurisdiction.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.